Drug Profile
Research programme: cardiovascular disorder therapeutics - Xel
Alternative Names: XEL 007DOLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Xel Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO, Tablet)
- 30 Mar 2010 Preclinical trials in Cardiovascular disorders in USA (PO)